Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $187,188 | 84 | 30.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $159,729 | 62 | 26.4% |
| Unspecified | $145,859 | 66 | 24.1% |
| Honoraria | $67,675 | 18 | 11.2% |
| Travel and Lodging | $33,826 | 72 | 5.6% |
| Food and Beverage | $10,993 | 142 | 1.8% |
| Education | $12.45 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| IGI Inc | $130,671 | 58 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $85,718 | 43 | $0 (2024) |
| Janssen Biotech, Inc. | $74,838 | 64 | $0 (2024) |
| Celgene Corporation | $62,287 | 75 | $0 (2024) |
| PFIZER INC. | $46,554 | 32 | $0 (2024) |
| GENZYME CORPORATION | $31,753 | 25 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $21,580 | 12 | $0 (2024) |
| Legend Biotech USA Inc. | $21,207 | 19 | $0 (2024) |
| ABBVIE INC. | $18,225 | 3 | $0 (2024) |
| Ichnos Sciences Inc. | $15,188 | 8 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $264,973 | 168 | IGI Inc ($130,671) |
| 2023 | $113,391 | 87 | Janssen Biotech, Inc. ($26,393) |
| 2022 | $81,687 | 55 | Janssen Biotech, Inc. ($28,515) |
| 2021 | $60,431 | 35 | Karyopharm Therapeutics Inc. ($25,458) |
| 2020 | $17,469 | 14 | Celgene Corporation ($9,802) |
| 2019 | $26,580 | 42 | Celgene Corporation ($22,900) |
| 2018 | $33,863 | 37 | Celgene Corporation ($25,331) |
| 2017 | $6,888 | 7 | Millennium Pharmaceuticals, Inc. ($6,715) |
All Payment Transactions
445 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,310.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,310.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,875.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,700.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,580.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $690.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $690.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $330.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $330.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $330.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $330.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $330.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $330.00 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $312.50 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $312.50 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $312.50 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $312.50 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $312.50 | Research |
| Study: ISB 1442-101 | ||||||
| 12/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $312.50 | Research |
| Study: ISB 1442-101 | ||||||
| 12/16/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $67.02 | General |
| 12/10/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,260.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $59.30 | General |
| Category: Oncology | ||||||
| 12/09/2024 | BeiGene USA, Inc. | — | Food and Beverage | In-kind items and services | $40.20 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1442-101 | IGI Inc | $130,671 | 58 |
| ISB 1442 | Ichnos Sciences Inc. | $15,188 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 306 | 1,229 | $477,750 | $89,722 |
| 2022 | 5 | 297 | 1,133 | $444,876 | $93,469 |
| 2021 | 6 | 266 | 1,089 | $451,196 | $108,638 |
| 2020 | 6 | 209 | 772 | $310,675 | $72,836 |
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 174 | 893 | $316,935 | $60,363 | 19.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 35 | 132 | $64,416 | $11,819 | 18.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 41 | 72 | $39,800 | $7,571 | 19.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 103 | $34,505 | $6,130 | 17.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 16 | $12,448 | $2,082 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $9,646 | $1,759 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 167 | 803 | $277,035 | $56,563 | 20.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 25 | 84 | $39,480 | $13,410 | 34.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 132 | $62,568 | $10,275 | 16.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 53 | 89 | $47,793 | $10,051 | 21.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 25 | 25 | $18,000 | $3,170 | 17.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 38 | 254 | $115,824 | $40,827 | 35.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 117 | 514 | $172,190 | $37,293 | 21.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 47 | 135 | $70,335 | $14,776 | 21.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 31 | 153 | $70,380 | $12,064 | 17.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $14,679 | $2,703 | 18.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 12 | 12 | $7,788 | $976.68 | 12.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 34 | 220 | $97,460 | $35,043 | 36.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 79 | 300 | $97,500 | $17,363 | 17.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 25 | 125 | $55,875 | $10,172 | 18.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 41 | 97 | $49,082 | $7,991 | 16.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $8,148 | $1,285 | 15.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 18 | 18 | $2,610 | $982.04 | 37.6% |
About Dr. Binod Dhakal, MD
Dr. Binod Dhakal, MD is a Internal Medicine healthcare provider based in Milwaukee, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/26/2010. The National Provider Identifier (NPI) number assigned to this provider is 1710218011.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Binod Dhakal, MD has received a total of $605,281 in payments from pharmaceutical and medical device companies, with $264,973 received in 2024. These payments were reported across 445 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($187,188).
As a Medicare-enrolled provider, Dhakal has provided services to 1,078 Medicare beneficiaries, totaling 4,223 services with total Medicare billing of $364,665. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Milwaukee, WI
- Active Since 01/26/2010
- Last Updated 10/01/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1710218011
Products in Payments
- XPOVIO (Drug) $85,718
- DARZALEX (Biological) $61,545
- Revlimid (Drug) $44,793
- ELREXFIO (Drug) $37,205
- CARVYKTI (Biological) $20,993
- VENCLEXTA (Drug) $18,225
- CARVYKTI (Drug) $15,194
- TECVAYLI (Biological) $14,136
- NINLARO (Drug) $12,866
- BLENREP (Biological) $11,550
- SARCLISA (Biological) $9,909
- DARZALEX (Drug) $4,981
- Kyprolis (Biological) $4,556
- Tecartus (Drug) $3,820
- ABECMA (Biological) $3,515
- TALVEY (Biological) $2,160
- Pomalyst (Drug) $1,597
- Cellsearch (Device) $688.78
- clonoSEQ (Device) $624.77
- Imbruvica (Drug) $122.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Milwaukee
Dr. Jeremiah Depta, M.d, M.D
Internal Medicine — Payments: $686,844
Dr. Lee Biblo, Md, MD
Internal Medicine — Payments: $382,388
Dr. Daniel Stein, M.d, M.D
Internal Medicine — Payments: $348,496
Nirav Shah, Md, MD
Internal Medicine — Payments: $280,591
Gilbert Jenouri, M.d, M.D
Internal Medicine — Payments: $229,172
Dr. Erik Stilp, Md, MD
Internal Medicine — Payments: $168,213